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S U M M A R Y
Background: We evaluated the performance of a galactomannan (GM) assay in bronchoalveolar lavage
(BAL) ﬂuid compared to serum samples for the diagnosis of invasive pulmonary aspergillosis (IPA) in
patients with hematological diseases.
Methods: Two hundred and ﬁfty-ﬁve bronchoscopies were performed on 230 patients. Bronchial and
alveolar samples from BAL ﬂuid as well as serum samples were analyzed in the GM assay.
Results: Twenty-eight cases of IPA (11%) were diagnosed. The sensitivity, speciﬁcity, positive predictive
value, and negative predictive value of the GM assay using a cut-off of 0.5 were 57.1%, 99.3%, 94.1%, and
92.5%, respectively, for the alveolar sample; 44.0%, 99.3%, 91.7%, and 91.4%, respectively, for the
bronchial sample; and 60.7%, 100%, 100%, and 92.9%, respectively, for serum. The highest sensitivity
(78.6%) with good speciﬁcity (98.6%) was obtained with a ‘triple detection’ of GM in bronchial, alveolar,
and serum samples. Neutropenia and antifungal therapy for only 24 h increased the sensitivity, while
antifungal treatment for 2 days decreased assay performance. Moreover, a trend towards a higher
volume of aspirated ﬂuid in GM-negative BAL (p = 0.092) was observed.
Conclusions: In contrast to recently published data, we found only moderate sensitivity, but high
speciﬁcity and high positive predictive value of the detection of GM in BAL ﬂuid. In addition, neutropenia,
antifungal therapy, and BAL standardization affected GM assay performance.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Invasive aspergillosis (IA) represents the most frequent invasive
fungal disease occurring in patients with hematological malignan-
cies, especially those with acute leukemia and after allogeneic
hematopoietic stem cell transplantation (HSCT).1,2 The lungs
comprise the primary site of IA in the vast majority of cases, and
therefore invasive pulmonary aspergillosis (IPA) represents the
most frequently occurring form of this disease.3 The high morbidity
and mortality rates of this infection, as well as difﬁculty in obtaining
an early diagnosis by conventional diagnostic procedures, has led to
the development of new non-culture based techniques.4* Corresponding author. Tel.: +420 53 2233642; fax: +420 53 2233603.
E-mail address: zracil@fnbrno.cz (Z. Racil).
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doi:10.1016/j.ijid.2011.09.011The detection of Aspergillus galactomannan (GM) in serum
using the Platelia Aspergillus enzyme immunoassay (EIA) (Bio-
Rad, France) has been studied extensively and represents a
sensitive, non-culture-based tool for the early diagnosis of IA in
patients with hematological malignancies.5 Moreover, GM can
also be detected in body ﬂuids other than serum, since a water-
soluble carbohydrate is released during hyphal tip growth.6
Recently, in vitro studies7 and animal models8 have shown that
during IPA, GM is released at an earlier time and at a higher
concentration in the bronchoalveolar lavage (BAL) ﬂuid than
in serum. Therefore, in an attempt to improve the sensitivity of
the GM assay in patients with IPA and to shorten the amount
of time to ﬁnal diagnosis, several groups have investigated the
utility of GM detection in BAL ﬂuid9 in non-hematological or
mixed populations,10–19 as well as in patients with hematological
malignancies.10,20–27ses. Published by Elsevier Ltd. All rights reserved.
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compared to regular serum GM screening methods remains a
matter of debate, primarily due to substantial inconsistencies in
the reported sensitivity, which ranges from 57%24 to 100%,20 even
in samples from patients with hematological malignancies.
The heterogeneity may be related to several factors that can
inﬂuence the results, including patient characteristics,28 variability
in the deﬁnitions of IPA,29,30 and different cut-off optical density
(OD) values of GM used in BAL ﬂuid.9 Moreover, there are several
covariates that may markedly inﬂuence the assay performance.
First, the administration of mold-active antifungal drugs (including
prophylactic treatment) that can inﬂuence the hyphal growth and
antigen release into body ﬂuids may affect the assay perfor-
mance.31,32 Second, neutropenia can lead to higher fungal bur-
den.32,33 Finally, there is a lack of BAL standardization among studies
that have analyzed the presence of GM in BAL ﬂuid, and therefore the
role of pre-analytical variables has not been assessed. It is well-
known that the return from the ﬁrst infused aliquot during lavage is
enriched for bronchial components, and should be analyzed
separately from the returns from subsequent aliquots, which are
of alveolar origin.34,35 In addition, the total volume of BAL ﬂuid varies
substantially among studies, and this can inﬂuence the fungal
antigen concentration, and consequently the sensitivity of the GM
assay. To date, no study has analyzed these pre-analytic factors.
The purpose of this study was to evaluate the performance and
clinical usefulness of GM detection in BAL ﬂuid compared to serum
samples for the diagnosis of IPA in a large cohort of patients with
hematological malignancies. Moreover, we compared assay
performance using bronchial and alveolar samples from BAL ﬂuid,
and analyzed the effect of the total BAL ﬂuid volume on the GM
assay. Finally, we investigated the role of neutropenia and mold-
active antifungal treatment on the sensitivity of the GM assay in
our study population.
2. Methods
2.1. Study population
We retrospectively reviewed the data obtained from patients
treated at the Department of Internal Medicine, Hematology and
Oncology of Masaryk University and University Hospital Brno,
Brno, Czech Republic, from July 2003 to September 2009, who
underwent a bronchoscopy with BAL for the evaluation of new
pulmonary inﬁltrates and who had BAL ﬂuid tested for GM. A
patient who underwent repeated sampling could be included in
the analysis if BAL had been performed on pulmonary inﬁltrate
that was clearly a new presentation. All patients gave informed
consent before the procedure and the Institutional Review Board
approved the study.
Twenty-six BAL samples obtained from patients who had a clear
false-positive result for GM in the serum, which was caused by the
administration of GM-positive lots of piperacillin–tazobactam and
amoxicillin–clavulanate or infusion of Plasma-Lyte solution
(Baxter Healthcare), were excluded from the analysis.
Patients were hospitalized in standard air controlled rooms or
in high-efﬁciency particulate air-ﬁltered single rooms. Patients
with neutropenia less than 1.0  109/l (48.2% of episodes) received
antifungal prophylaxis at the time of the bronchoscopy; however,
only 5.9% of the patients received mold-active drugs.
Regular monitoring of serum GM was performed twice a week
in all patients with acute leukemia and in patients who received an
allogeneic HSCT. For all other patients, the serum GM was tested
only in cases of pulmonary inﬁltrate or febrile neutropenia. If
febrile neutropenia did not respond to antibiotic treatment, the
patients received empirical antifungal treatment, which predomi-
nantly consisted of conventional amphotericin B or echinocandin.This treatment was followed by a routine full diagnostic work-up
for invasive fungal disease, including a high-resolution lung
computed tomography (CT) and BAL in the case of pulmonary
inﬁltrates.
2.2. Fiberoptic bronchoscopy and sample investigation
The site of the ﬁberoptic bronchoscopy was guided by a high-
resolution lung CT. Eight to 10 sequential, 20-ml aliquots of sterile
saline solution were infused into the lower respiratory tract, and
each aliquot was immediately aspirated. The return from the ﬁrst
aliquot (bronchial sample) was processed separately from the
returns from the subsequent aliquots, which were pooled together
and homogenized (alveolar sample). Both portions of BAL ﬂuid
were submitted for cytology assessment, direct examination,
bacterial, fungal, and mycobacterial culture, and GM detection.
Viral and Pneumocystis jiroveci screening by PCR was performed on
the alveolar samples only.
2.3. GM detection
GM detection was performed for both samples of BAL ﬂuid
separately (i.e., bronchial and alveolar samples). Moreover, the
Platelia Aspergillus GM EIA (Bio-Rad, France) test was used to
detect GM in serum samples taken immediately prior to the
bronchoscopy. The BAL specimens were centrifuged at 1000 rpm
for 10 min and the supernatant was used for GM detection. The
Platelia Aspergillus GM EIA test was performed according to the
manufacturer’s recommendations for testing serum samples. The
assay was performed three times a week in a routine microbiology
laboratory. Samples were stored at 20 8C until used for testing. All
tests with an OD index 0.5 were repeated on the same specimen.
2.4. Case deﬁnition and statistical analysis
The medical records of all patients were reviewed, and each
case of pulmonary inﬁltrate for which BAL was performed was
classiﬁed as proven, probable, possible, or no IPA based on the
revised European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) case deﬁnition.30 The detection of GM in BAL
ﬂuid and serum samples obtained during bronchoscopy was not
included as one of the microbiological criteria.
The Mann–Whitney test or Kruskal–Wallis analysis of variance
(ANOVA) was used to compare independent subgroups of
bronchoscopies in continuous variables, and the Wilcoxon test
was used for a pair-wise comparison. A two-sided p-value of <0.05
was considered statistically signiﬁcant. The sensitivity, speciﬁcity,
positive predictive value (PPV), and negative predictive value
(NPV) were calculated when bronchoscopies without IPA were
considered as being true-negatives and episodes with proven and
probable IPA were considered as true-positives. A receiver
operating characteristic (ROC) curve and area under the curve
(AUC) were used to estimate the discriminatory capability of the
GM assay performed in both samples of BAL ﬂuid and of the serum
sample obtained during bronchoscopy for IPA detection. For
statistical analysis, the software Statistica version 9.0 (StatSoft)
and R (R Development Core Team) were used.
3. Results
During the study period, the bronchial and alveolar samples of
BAL ﬂuid obtained from 255 bronchoscopies in 230 patients were
tested for GM. The baseline characteristics are shown in Table 1.
IPA was documented in 105 (41.2%) of the bronchoscopies
Table 1
Baseline characteristics
Number of patients 230
Number of BAL 255
Number of BAL/patient, median (range) 1 (1–3)
Men, n (%) 151 (65.7%)
Women, n (%) 79 (34.3%)
Age (years), median (range) 54 (18–79)
Diagnosis, n (%)
AML/MDS 83 (36.1%)
NHL 46 (20%)
CLL 23 (10%)
MM 16 (7.0%)
ALL 15 (6.5%)
CML 13 (5.7%)
Other 34 (14.8%)
Probability of IPA at the time of BAL, n (%)
Proven IPA 7 (2.7%)
Probable IPA 21 (8.2%)
Possible IPA 77 (30.2%)
No IPA (control) 150 (58.8%)
Neutropenia (<1.0  109/l) at the time of BAL, n (%)
All samples
Yes 123 (48.2%)
No 125 (49.0%)
NA 7 (2.7%)
Proven and probable IPA
Yes 18 (64.3%)
No 9 (32.1%)
NA 1 (3.6%)
No IPA
Yes 48 (32%)
No 98 (65.3%)
NA 4 (2.7%)
Mold-active antifungals at the time of BAL, n (%)
All samples
Yes 125 (49.0%)
No 123 (48.2%)
NA 7 (2.7%)
Proven and probable IPA
Yes 20 (71.4%)
No 8 (28.6%)
NA 0 (0%)
No IPA
Yes 40 (26.7%)
No 103 (68.7%)
NA 7 (4.7%)
BAL, bronchoalveolar lavage; AML, acute myeloid leukemia; MDS, myelodysplastic
syndrome; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM,
multiple myeloma; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous
leukemia; IPA, invasive pulmonary aspergillosis; NA, not available.
Figure 1. Distribution of the GM OD index values in the bronchial and alveolar
samples from BAL ﬂuid according to the EORTC/MSG deﬁnition for IPA (GM,
galactomannan; OD, optical density; BAL, bronchoalveolar lavage; EORTC/MSG,
European Organization for Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group; IPA, invasive pulmonary aspergillosis).
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and probable IPA were fulﬁlled in only 28 episodes (11%).
Neutropenia less than 1.0  109/l and treatment (including
prophylaxis) with mold-active drugs occurred during 48.2% and
49.0% of the BAL, respectively.
3.1. Assay performance with the bronchial and alveolar samples from
BAL ﬂuid
The GM OD index values for all patients according to the
probability of IPA, as well as for both analyzed samples of BAL ﬂuid,
are presented in Figure 1. The median GM OD index values for
bronchial and alveolar samples from BAL ﬂuid were signiﬁcantly
higher in the proven and probable IPA episodes compared to the
possible IPA episodes and control BAL (no IPA) (p < 0.001).
However, there was no difference in the median GM values
between the bronchial and alveolar samples from BAL ﬂuid among
the proven/probable IPA episodes (OD index of 0.3 for the
bronchial samples vs. 0.86 for the alveolar samples, p = 0.904).
The GM assay performance for both samples of BAL ﬂuid
separately or in the combined analysis for different cut-off OD
indexes is shown in Table 2. ROC curves for bronchial and alveolarsamples are shown in Figure 2. A GM cut-off OD index of 0.5 revealed
the best sensitivity for all analyses with only a limited decrease in
speciﬁcity or PPV. The detection of GM in the alveolar sample
exhibited better sensitivity compared to the bronchial sample of BAL
ﬂuid. However, in two (7.1%) of the bronchoscopies performed for
proven/probable IPA, the alveolar sample of BAL ﬂuid had a GM OD
index of < 0.5, while the bronchial sample was positive at this cut-
off value. Thus, the highest sensitivity was achieved when a
combined detection was performed on both samples of BAL ﬂuid,
and if any of the samples achieved the GM OD index cut-off value, the
patient’s BAL ﬂuid was marked as GM-positive.
3.2. Assay performance – serum
A serum sample obtained at the time of the BAL, which was not
included in the microbiological criteria for stratiﬁcation of IPA
probability, had the best performance parameters at a cut-off OD
index of 0.5 (Table 2 and Figure 2). Interestingly, GM detection in
this single serum sample and at a cut-off OD index of 0.5 had better
sensitivity, speciﬁcity, PPV, and NPV compared to the bronchial or
alveolar samples of BAL ﬂuid alone (Table 2). However, ﬁve of 11
(45.5%) patients with a negative GM test in the serum (for a cut-off
of 0.5) had positive bronchial or alveolar samples of BAL ﬂuid at the
same cut-off OD value. Therefore, not surprisingly, the best
performance of the Platelia Aspergillus test was achieved when the
‘triple testing’ (a GM OD index of >0.5 in the bronchial or alveolar
samples of BAL ﬂuid or serum sample obtained during bronchos-
copy) was performed, which showed a sensitivity of 78.6% (Table
2).
3.3. BAL ﬂuid culture and microscopy
Only three out of 28 BAL ﬂuid samples obtained during episodes
of proven/probable IPA were culture-positive for Aspergillus sp
(three Aspergillus fumigatus). However, none of these samples were
positive for fungal hyphae by microscopic analysis. Thus, the
combined sensitivity of these conventional microbiological meth-
ods was only 10.7%. Moreover, two out of three samples had a GM
Table 2
The sensitivities, speciﬁcities, positive predictive values, and negative predictive values, and their 95% conﬁdence intervals for galactomannan detected in different sample
types and evaluated at different cut-off galactomannan optical density indexes. Only samples from bronchoscopies with probable and proven invasive pulmonary
aspergillosis were used for the analysis
Cut-off OD
0.5 1.0 1.5
BAL – bronchial sample only
Sensitivity 44.0% (24.4–65.1%) 32.0% (14.9–53.5%) 32.0% (14.9–53.5%)
Speciﬁcity 99.3% (96.3–99.9%) 100% (96.3–100%) 100% (96.3–100%)
PPV 91.7% (61.5–99.8%) 100% (51.8–100%) 100% (51.8–100%)
NPV 91.4% (85.9–95.2%) 89.8% (84.1–93.9%) 89.8% (84.1–93.9%)
BAL – alveolar sample only
Sensitivity 57.1% (37.2–75.5%) 46.4% (27.5–66.1%) 46.4% (27.5–66.1%)
Speciﬁcity 99.3% (96.3–99.9%) 100% (96.4–100%) 100% (96.4–100%)
PPV 94.1% (71.3–99.9%) 100% (66.1–100%) 100% (66.1–100%)
NPV 92.5% (87.3–96.1%) 90.9% (85.4–94.8%) 90.9% (85.4–94.8%)
Bronchial and alveolar samplea
Sensitivity 36.0% (18.0–57.5%) 28.0% (12.1–49.4%) 28.0% (12.1–49.4%)
Speciﬁcity 100% (96.3–100%) 100% (96.3–100%) 100% (96.3–100%)
PPV 100% (55.5–100%) 100% (47.3–100%) 100% (47.3–100%)
NPV 90.3 (84.7–94.4%) 89.2% (83.5–93.5%) 89.2% (83.5–93.5%)
Bronchial or alveolar sample
Sensitivity 64.3% (44.1–81.4%) 51.9% (31.9–71.3%) 51.9% (31.9–71.3%)
Speciﬁcity 98.7% (95.2–99.8%) 100% (96.3–100%) 100% (96.3–100%)
PPV 90.0% (68.3–98.8%) 100% (68.1–100%) 100% (68.1–100%)
NPV 93.6% (88.6–96.9%) 92.0 (86.7–95.7%) 92.0 (86.7–95.7%)
Serum on the day of BALb
Sensitivity 60.7% (40.6–78.5%) 39.3% (21.5–59.4%) 21.4% (8.3–41.0%)
Speciﬁcity 100% (96.2–100%) 100% (96.2–100%) 100% (96.2–100%)
PPV 100% (72.7–100%) 100% (61.5–100%) 100% (42.1–100%)
NPV 92.9% (87.7–96.4%) 89.5% (83.7–93.8%) 86.8% (80.7–91.6%)
Serum at BALb or bronchial or alveolar sample
Sensitivity 78.6% (59.0–91.7%) 63.0% (42.4–80.6%) 55.6% (35.3–74.5%)
Speciﬁcity 98.6% (95.1–99.8%) 100% (96.2–100%) 100% (96.2–100%)
PPV 91.7% (73.0–99.0%) 100% (72.7–100%) 100% (69.8–100%)
NPV 96.0% (91.4–98.5%) 93.5% (88.5–96.9%) 92.4% (87.0–96.0%)
OD, optical density; BAL, bronchoalveolar lavage; PPV, positive predictive value; NPV, negative predictive value.
a Both samples must be positive at the selected cut-off OD index to mark the result as positive.
b For serum samples – the test is positive if one sample already revealed the pre-speciﬁed cut-off OD.
Z. Racil et al. / International Journal of Infectious Diseases 15 (2011) e874–e881 e877OD of >0.5 in the bronchial or alveolar samples from BAL ﬂuid. The
only GM-negative patient, who presented with pulmonary
interstitial ﬁbrosis after an allogeneic HSCT, had a borderline
positive GM test in a bronchial sample of the BAL ﬂuid (GM OD
index of 0.46). The serum GM test in this patient was negative (GM
OD index of 0.07).
3.4. Parameters that affect the GM assay sensitivity in BAL ﬂuid
We analyzed the effects of neutropenia, mold-active antifungal
treatment, and the volume of administered ﬂuid during BAL on
assay performance. Two-thirds of the patients with proven/
probable IPA had a neutrophil count of <1.0  109/l at the time
of bronchoscopy. The sensitivity of the GM test performed on anyTable 3
The sensitivity of the galactomannan assay in proven and probable invasive pulmonary a
inﬂuence of neutropenia and mold-active antifungal treatment at the time of broncho
BAL – bronchial
sample
BAL – alveolar
sample
Neutropenia <1.0  109/lb
Yes (n = 18) 50.0% 66.7% 
No (n = 9) 25.0% 33.3% 
Antifungals 1 day only
Yes (n = 6) 83.3% 100% 
No (n = 8) 28.6% 50.0% 
Antifungals 2 days
Yes (n = 14) 33.3% 42.9% 
No (n = 14) 53.8% 71.4% 
BAL, bronchoalveolar lavage; OD, optical density.
a For serum samples – the test is positive if one sample already revealed the cut-off
b Neutrophil count was not known for one patient with proven/probable invasive asof the BAL ﬂuid samples from neutropenic patients was
approximately two times higher than from non-neutropenic
patients (Table 3). Although less signiﬁcant, the sensitivity of
the assay for serum samples obtained during bronchoscopy was
higher in neutropenic patients than in non-neutropenic patients
(66.7% vs. 55.6%, respectively).
For the majority (71.4%) of proven/probable IPA episodes,
patients received mold-active antifungal therapy. However, the
length of antifungal treatment at the time of the BAL procedure
differed signiﬁcantly, with a range of 1–25 days and a median
duration of 2.5 days. The sensitivity of GM detection in the
bronchial and alveolar samples from BAL ﬂuid, as well as in serum,
decreased signiﬁcantly when the treatment had lasted 2 days at
the time of the bronchoscopy (Table 3). However, in patients whospergillosis cases using a cut-off galactomannan optical density index of 0.5, and the
scopy
Bronchial or
alveolar sample
Bronchial and
alveolar sample
Serum at the day
of BAL onlya
72.2% 43.8% 66.7%
44.4% 12.5% 55.6%
100% 83.3% 100%
62.5% 14.3% 37.5%
50.0% 25.0% 57.1%
78.6% 46.2% 64.3%
 OD.
pergillosis.
Figure 3. Distribution of the GM OD index values in the bronchial and alveolar
samples of BAL ﬂuid in proven/probable IPA episodes according to the length of
treatment with mold-active antifungal drugs (GM, galactomannan; OD, optical
density; BAL, bronchoalveolar lavage; IPA, invasive pulmonary aspergillosis).
Figure 2. ROC curves for GM detection in bronchial and alveolar samples of BAL
ﬂuid and serum obtained during the bronchoscopy. The AUC for GM detection in the
bronchial sample = 0.825, alveolar sample = 0.853, and in serum obtained at the
time of BAL = 0.832 (ROC, receiver operating characteristic; GM, galactomannan;
BAL, bronchoalveolar lavage; AUC, area under the curve).
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bronchoscopy, the sensitivity dramatically increased to 83.3% in
the bronchial sample and 100% in the alveolar sample of BAL ﬂuid
and 100% in the serum sample, compared to patients who did not
receive antifungal treatment (Table 3). Similarly, the median GM
OD index in both samples of BAL ﬂuid was highest in patients with
episodes of proven/probable IPA who had been treated with mold-
active antifungals for only 1 day (Figure 3), compared to patients
who had received a longer treatment period of antifungals or no
treatment at all.
Finally, we analyzed the relationship between the volume of
administered solution used for the BAL or the volume of aspirated
BAL ﬂuid and the positivity of the GM assay from the alveolar
sample. Although there was no signiﬁcant relationship between
the amount of administered solution and the GM assay (p = 0.171),
there was a trend towards a higher volume of aspirated ﬂuid in
GM-negative BAL (p = 0.092) (Figure 4).Figure 4. The mean, SE, and 95% CI of aspirated BAL ﬂuid volume in proven/probable
IPA episodes according to the GM OD index (SE, standard error; CI, conﬁdence
interval; BAL, bronchoalveolar lavage; IPA, invasive pulmonary aspergillosis; GM,
galactomannan; OD, optical density).
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In this study, which represents the largest cohort of patients
with hematological diseases published to date, we found moderate
sensitivity as well as excellent speciﬁcity and PPV for the detection
of GM in BAL ﬂuid when a cut-off OD index of 0.5 was used.
The sensitivity for the detection of GM in BAL ﬂuid (alveolar
sample; 57.1%) determined in this study was lower than that
published in the majority of recent studies on hematological
patients, which have reported a sensitivity with the same cut-off
OD index ranging from 73% to 100%.10,22,23,25–27 The only exception
to these previous ﬁndings is the study by Bergeron et al., which
showed a sensitivity of 57.6%, very close to the one determined in
our study.24
There are several potential reasons for the sensitivity differ-
ences in the detection of GM in BAL ﬂuid between published
studies and our data. First, the deﬁnition of patients with IPA could
differ among the studies (i.e., differences in diagnostic criteria of IA,
the use of serum GM as part of the criteria, or the inclusion of
possible IA cases for the calculation of the test sensitivity).
However, this is most likely not the reason for the difference, since
the vast majority of recent studies, including our study, used
EORTC/MSG 2008 criteria30 and did not include the possibility of IA
in the analysis.
Second, the composition of the analyzed hematological
population, as well as the degree and type of immunodeﬁciency,
varied among studies. For example, 88% of the patients in the study
by Musher et al. underwent HSCT,10while in the study by Hsu et al.,
only 20% were treated with an HSCT; however, 90% of the patients
had neutropenia.25 It is well-known that the GM assay has a better
performance on serum samples from patients with neutropenia.36
However, the only study that has analyzed the effect of
neutropenia on the sensitivity of GM detection in BAL ﬂuid in
hematological patients did not ﬁnd any difference in the sensitivity
between patients with or without a decreased neutrophil count.24
Nevertheless, contrary to published data, that study also did not
ﬁnd any difference in the sensitivity of the GM assay in serum
samples.24 In our study, we found signiﬁcantly better sensitivity in
the assay for patients with neutropenia. The sensitivity was almost
two times greater in neutropenic patients compared to non-
neutropenic patients in all analyzed samples of lavage ﬂuid. These
ﬁndings are in agreement with the recognized differences in
pathogenesis and disease progression of aspergillosis in animal
studies.37,38 In neutropenic animals, intensive hyphal growth, high
pulmonary fungal burden, and angioinvasion results in high GM
concentrations in both the lungs and serum. In contrast,
pulmonary inﬂammation is the main cause of disease progression
in non-neutropenic, steroid-immunosuppressed animals. More-
over, the fungal burden is low with little angioinvasion in these
animals, which results in GM levels close to the detection
threshold.39
Third, prophylactic or empirical administration of mold-active
antifungal therapies may be another possible cause of the
variability seen in the test sensitivity among published studies.
However, the data in the literature are controversial. While some
studies report no impact of antifungal therapies on assay
sensitivity for BAL ﬂuid,22,24 other studies describe a decreased
sensitivity in patients with antifungal treatment lasting 3 days,20
and still others have shown that the administration of antifungal
agents seems to increase the sensitivity of GM detection in BAL
ﬂuid.10,26 Our study results represent a combination of both of
these concepts and provide an explanation for these discrepancies
(Table 3). We conﬁrmed the conclusions of the study by Luong
et al.,26 which showed that in clinical practice, empirical antifungal
treatment reﬂects a physician’s suspicion of fungal disease and
may serve as a surrogate marker for the infection. Thus, the assaysensitivity in our patient group was signiﬁcantly higher in
individuals who had just started empirical treatment with
antifungal drugs and who had received only one or two doses.
However, treatment with antifungal therapy for 2 days promptly
decreased fungal load and concomitantly decreased the assay
sensitivity for both samples of BAL ﬂuid, as well as serum. These
results also conﬁrm the ﬁndings of Becker et al.20 and Marr et al.31
Finally, we hypothesize that the studies that did not ﬁnd any effect
of antifungal therapy on assay performance22,24 may indeed
identify an effect if the two groups of patients with different
lengths of fungal treatment described in our study were analyzed
together.
Finally, the most crucial factor that affects the sensitivity of GM
detection in BAL ﬂuid is most likely the standardization of BAL
performance. The volume of collected BAL ﬂuid can inﬂuence the
GM concentration and consequently the assay reactivity.25,26 Our
data have for the ﬁrst time proven this hypothesis, as we have
found a trend towards a higher volume of aspirated ﬂuid in GM-
negative BAL (Figure 4). Since the volume of collected BAL ﬂuid is
dependent (besides other factors) on the volume of instilled sterile
saline during the bronchoscopy, it is a critical factor for differences
in GM assay performance, and there is signiﬁcant variability in the
amount of instilled solution among studies in the literature,
ranging from 40 to 200 ml.23,26 Moreover, while the majority of
studies performed GM detection in the homogenized alveolar
sample of the BAL ﬂuid (as recommended35), there are some
instances where GM was detected in the ﬁrst obtained aliquot of
BAL ﬂuid (bronchial sample).25 This could be an additional factor
affecting the variability in assay performance among the published
studies to date, since our study has shown a signiﬁcantly lower
sensitivity of GM detection in the bronchial sample of BAL ﬂuid
compared to the alveolar sample. Nevertheless, combining the GM
assay results from both samples of the BAL ﬂuid could lead to
further improvements in assay sensitivity, because in some of our
IPA cases, only the bronchial and not the alveolar sample was
positive (Table 2).
Several studies have reported low speciﬁcity and PPV of GM
detection in BAL ﬂuid using a GM cut-off OD index of 0.523,25–27
due to the high frequency of false-positive results that were mainly
caused by the administration of b-lactam antibiotics.26 These
authors recommended using a higher cut-off OD index than 0.5 in
order to improve the assay performance. In our large study
population, patients with explicit false-positive results from the
detection of GM in serum caused by b-lactam antibiotics or
Plasma-Lyte solution40,41 were excluded from the analysis. After
exclusion of these patients, we found that the speciﬁcity and PPV of
the assay were very high (99.3% and 94.1%, respectively) when a
cut-off OD of 0.5 was used, which was not signiﬁcantly improved
by increasing the cut-off value (Table 2).
There are only a few studies to date comparing the sensitivity of
GM detected in BAL ﬂuid and serum samples. There are two
important limitations to this type of analysis. First, serum GM
detection is generally used as a criterion for the diagnosis of
probable IA, and therefore an analysis that evaluates assay
performance in IA cannot be performed. Second, the samples
used for GM detection are usually not obtained at the same time or
even same day as when the BAL is performed. Becker et al.20
published the only study that did not use serum GM as a criterion
for IA, and found signiﬁcantly higher sensitivity of GM detection in
BAL ﬂuid compared to serum (100% vs. 47%, respectively).
However, the serum GM was not obtained at the same time as
the BAL procedure, and a cut-off OD index of 1.0 was used for both
serum and BAL ﬂuid. In our study, the serum samples were
obtained immediately prior to the BAL procedure, and the result of
this sampling was not used as a criterion for IA diagnosis. Using a
cut-off OD index of 0.5 resulted in a sensitivity of 60.7%, which was
Z. Racil et al. / International Journal of Infectious Diseases 15 (2011) e874–e881e880similar to the results obtained from the alveolar sample of BAL ﬂuid
(57.1%) and the combined analysis of bronchial and alveolar
samples from BAL ﬂuid (64.3%) (Table 2). However, it must be
noted that some patients had negative alveolar or bronchial
samples from the BAL ﬂuid while exhibiting a positive GM test
result from the serum sample taken prior to the BAL procedure.
Thus, the highest sensitivity of 78.6% with high speciﬁcity and an
acceptable PPV was achieved when ‘triple testing’ was performed,
which included a GM OD greater than 0.5 in the alveolar or
bronchial samples from the BAL ﬂuid or in serum (Table 2).
The limitations of our study could be the retrospective design
and the exclusion of patients who had clear false-positive assay
results from serum analysis. However, since there is over 10 years
of experience with this assay, virtually all major factors that could
cause a false-positive in serum are well described and known.
Therefore, in our opinion, patients with false-positive results
caused by a known interference factor should be excluded from a
retrospective study. This approach will more closely reﬂect what
occurs in current daily clinical practice rather than repeatedly
reporting the occurrence of false-positive results caused by b-
lactam antibiotics or gluconate-containing solutions,40,41 even
though at present, these drugs and solutions would not be given to
patients where GM is monitored.
In conclusion, our retrospective study, which is the largest
published study on hematological patients to date, found moderate
sensitivity as well as high speciﬁcity and PPV of the GM assay in BAL
ﬂuid (alveolar sample) when a cut-off OD of 0.5 was used.
Importantly, the moderate sensitivity of the GM test in BAL ﬂuid
found in the present study is in contrast to the vast majority of
published reports and meta-analyses performed to date. In addition,
the moderate sensitivity of the GM test in BAL ﬂuid was close to that
found in serum samples obtained at the same time as the BAL
procedure. Therefore, in this study, we have clearly identiﬁed three
major factors that affect assay performance: (1) the need for BAL
standardization, including the sample of BAL ﬂuid used for analysis
and the volume of instilled solution; (2) the role of antifungal
therapy and the treatment duration prior to the BAL procedure; and
(3) the higher utility of the assay in neutropenic patients. Moreover,
we have demonstrated the advantage of combining the assay results
from the BAL ﬂuid and serum samples obtained at the same time for
the detection of GM. Thus, the best assay performance for detection
of IPA is obtained when a ‘triple’ GM detection method is used,
including the simultaneous detection of GM in the bronchial and
alveolar samples from BAL ﬂuid as well as serum from neutropenic
patients who have just initiated empirical antifungal therapy due to
a clinical suspicion of disease.
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